Evidence Hub

Two Cases of Post-Kidney Transplantation Thrombotic Microangiopathy From a Single Donor With Candidemia

Shi T, Schwieterman WH, Eletta O, Cuffy M, Plews RL

Transplantation proceedings, 2025

Abstract

Thrombotic microangiopathy (TMA) secondary to donor-derived infections remains a rare, yet serious source of graft loss and increased patient morbidity and mortality. Among TMA etiologies, donor-derived fungal infections remain particularly challenging to test for pre-operatively and treat post-operatively. We describe 2 cases of post-kidney transplant TMA from a single donor with suspected candidemia. Despite prophylactic treatment for Candida with fluconazole and eculizumab for TMA, 1 of the 2 patients unfortunately succumbed to TMA-related complications. The other patient, who also received fluconazole and eculizumab, had persistent hemolysis and ultimately required a transplant nephrectomy. Following nephrectomy, the patient's symptoms and laboratory values improved and the patient was able to be discharged to inpatient rehab before returning home. Despite appropriate treatment for Candida and TMA, patient outcomes were unfavorable. These 2 cases underscore the difficulties in treating TMA in the setting of organ transplantation and candidemia, pointing to the necessity for more research into improved treatment approaches.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free